{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:24:05Z","timestamp":1785425045980,"version":"3.56.0"},"reference-count":58,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BeOne Medicines ULC"},{"id":[{"id":"https:\/\/ror.org\/03saz3d95","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Hoffmann-La Roche Canada"},{"id":[{"id":"https:\/\/ror.org\/006hrz834","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Incyte Biosciences Canada"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Relapsed and\/or refractory follicular lymphoma (R\/R FL) remains a therapeutic challenge due to its chronic relapsing course and increasingly complex treatment landscape. Novel therapies, including immunomodulatory combinations, bispecific antibodies (BsAbs), Bruton tyrosine kinase inhibitors, and chimeric antigen receptor (CAR) T-cell therapies, have expanded treatment options and increased the complexity of treatment selection and sequencing. The Canadian Hematology Consensus Group (CHCG) convened a national panel of lymphoma experts to develop evidence-informed consensus recommendations for the management of adults with R\/R FL in the Canadian context. Clinical questions informed a structured literature review of studies published through February 2026, including randomized trials, phase II studies, observational data, conference proceedings, and relevant guidelines. Recommendations were developed using a modified Delphi consensus process and graded using a framework adapted from the British Committee for Standards in Haematology. Key recommendations include repeat biopsy to exclude histologic transformation at relapse, individualized treatment selection based on timing of relapse and patient-specific factors, preferential use of lenalidomide-rituximab (LenR)-based triplet combinations in most second-line settings, and incorporation of BsAb and CAR T-cell therapy in third-line and later disease. These recommendations aim to provide practical guidance for Canadian clinicians managing patients with R\/R FL.<\/jats:p>","DOI":"10.3390\/curroncol33080451","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:52:01Z","timestamp":1785228721000},"page":"451","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Canadian Hematology Consensus Group Recommendations for the Management of Relapsed and\/or Refractory Follicular Lymphoma"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1708","authenticated-orcid":false,"given":"Carolyn","family":"Owen","sequence":"first","affiliation":[{"name":"Division of Hematology and Hematological Malignancies, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-5866","authenticated-orcid":false,"given":"Christopher","family":"Lemieux","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Centre Int\u00e9gr\u00e9 de Canc\u00e9rologie, CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC G1J 0J9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bosch","sequence":"additional","affiliation":[{"name":"Hematological Oncology, University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Davison","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Forward","sequence":"additional","affiliation":[{"name":"Division of Hematology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 4R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopesh","family":"Kanasara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cancer Care Manitoba, University of Manitoba, Winnipeg, MB R3E OV9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Margaret","family":"Keating","sequence":"additional","affiliation":[{"name":"Division of Hematology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 4R2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Prica","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cancer Care Manitoba, University of Manitoba, Winnipeg, MB R3E OV9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Stewart","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematological Malignancies, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5369-1501","authenticated-orcid":false,"given":"Abi","family":"Vijenthira","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"BC Cancer Centre for Lymphoid Cancer, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"ref_1","unstructured":"Canadian Cancer Society\u2019s Advisory Committee on Cancer Statistics (2025). Canadian Cancer Statistics 2025, Canadian Cancer Society\u2019s Advisory Committee on Cancer Statistics."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3747\/co.23.3405","article-title":"Emerging therapies for the treatment of relapsed or refractory follicular lymphoma","volume":"23","author":"MacDonald","year":"2016","journal-title":"Curr. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e250048","DOI":"10.6004\/jnccn.2025.0048","article-title":"NCCN Guidelines\u00ae Insights: B-Cell Lymphomas 3.2025","volume":"23","author":"Zelenetz","year":"2025","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1016\/j.arthro.2025.03.038","article-title":"Guidelines for Designing and Conducting Delphi Consensus Studies: An Expert Consensus Delphi Study","volume":"41","author":"Hohmann","year":"2025","journal-title":"Arthroscopy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.18083","article-title":"Guideline for the first-line management of Classical Hodgkin Lymphoma\u2014A British Society for Haematology guideline","volume":"197","author":"Follows","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","article-title":"Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Eyre","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_13","unstructured":"Alberta Health Services (2019). Clinical Practice Guideline Lyhe-002, Alberta Health Services. Version 11."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Pe\u00f1alver, F.J., Magnano, L., Alonso-\u00c1lvarez, S., Jim\u00e9nez-Ubieto, A., L\u00f3pez-Guillermo, A., and Sancho, J.M. (2026). Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025. Cancers, 18.","DOI":"10.3390\/cancers18030395"},{"key":"ref_15","unstructured":"University Health Network (2026, April 15). Princess Margaret Cancer Centre Clinical Practice Guidelines: Lymphoma. Available online: https:\/\/www.uhn.ca\/PrincessMargaret\/Health_Professionals\/Programs_Departments\/Documents\/CPG_Lymphoma_AggressiveLymphoma.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.16872","article-title":"The investigation and management of follicular lymphoma","volume":"191","author":"McNamara","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/S2352-3026(25)00034-1","article-title":"Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: Long-term results of a randomised, phase 3 trial","volume":"12","author":"Northend","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/cam4.4588","article-title":"The outcome of watchful waiting in patients with previously treated follicular lymphoma","volume":"11","author":"Fujino","year":"2022","journal-title":"Cancer Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma","volume":"26","author":"Gill","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101270","DOI":"10.1016\/j.blre.2025.101270","article-title":"PET scan for the detection of histological transformation of follicular lymphoma: A systematic review of diagnostic performance","volume":"71","author":"Sorigue","year":"2025","journal-title":"Blood Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/bjr\/tqaf028","article-title":"18F-FDG PET or PET\/CT in detecting high-grade transformation of chronic lymphocytic leukaemia and indolent lymphomas: A systematic review and meta-analysis","volume":"98","author":"Lee","year":"2025","journal-title":"Br. J. Radiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1111\/bjh.70181","article-title":"Transformation and causes of death in follicular lymphoma: A Finnish nationwide population-based study","volume":"207","author":"Kalashnikov","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-020-0299-0","article-title":"Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: A single-center experience","volume":"10","author":"Mozas","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: Survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk Factors and Outcomes for Patients with Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1182\/blood-2024-210922","article-title":"Rate of Transformation and Secondary Malignancies in Follicular Lymphoma Patients Treated with First-Line Bendamustine Rituximab and Rituximab Maintenance","volume":"144","author":"Kuruvilla","year":"2024","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/10428194.2025.2482890","article-title":"Analysis of a cancer-care based diagnosis program for lymphoma","volume":"66","author":"Owen","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e70414","DOI":"10.1002\/cam4.70414","article-title":"Diagnostic Performance and Safety of Ultrasound-Guided Core Needle Biopsy for Diagnosing Lymphoma: A Systematic Review and Meta-Analysis","volume":"14","author":"Kwon","year":"2025","journal-title":"Cancer Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108990","DOI":"10.1016\/j.ejrad.2020.108990","article-title":"Image-guided core needle biopsy in the diagnosis of malignant lymphoma: Comparison with surgical excision biopsy","volume":"127","author":"Chatani","year":"2020","journal-title":"Eur. J. Radiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/bjh.70277","article-title":"The progression at 24\u2009months (POD24) induces a high risk of transformation of follicular lymphoma: A systematic biopsy verification","volume":"208","author":"Picardi","year":"2026","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.7150\/jca.54434","article-title":"Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months","volume":"12","author":"Yoon","year":"2021","journal-title":"J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(25)01778-7","article-title":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): A global, phase 3, randomised controlled trial","volume":"407","author":"Sehn","year":"2026","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","article-title":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): A global, open-label, randomised, phase 3 trial","volume":"407","author":"Falchi","year":"2026","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall Survival Benefit in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study","volume":"36","author":"Cheson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study","volume":"35","author":"Rummel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: A multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","article-title":"Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis","volume":"24","author":"Casulo","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","article-title":"Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group","volume":"24","author":"Jurinovic","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1200\/JCO-25-00668","article-title":"Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma","volume":"43","author":"Neelapu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: The phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ajh.70225","article-title":"Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed\/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis","volume":"101","author":"Bartlett","year":"2026","journal-title":"Am. J. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: Primary efficacy and safety analysis in phase 2 ELM-2 trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2021-148778","article-title":"Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R\/R) Follicular Lymphoma (FL)","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2025-227","article-title":"Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed\/refractory follicular lymphoma","volume":"146","author":"Zinzani","year":"2025","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.31264","article-title":"Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR","volume":"124","author":"Sureda","year":"2018","journal-title":"Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/451\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:08:33Z","timestamp":1785229713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["curroncol33080451"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33080451","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}